NEWS ON ONE CLICK
http://www.theoneclickgroup.co.uk
1. Courage Is Contagious - Whistleblower Guidelines
WikiLeaks Editor Julian Assange -
The internet whistleblower era has arrived
(Caption & Pic Courtesy of One Click)
WikiLeaks editor, Julian Assange, provides guidelines to whistleblowers in this video after speaking at the Centre for Investigative Journalism’s Summer School 2010. Julian is the main architect of the remarkably successful public interest project WikiLeaks. This is a web-based platform for whistleblowers that for offers a secure place to publish internal and often secret documents that disclose injustice, corruption and murder, in the public interest. WikiLeaks provides something entirely new. It provides a secure, military grade protection programme for whistleblowers which has enabled the safe transmission of important evidence to the public. So far, not one amongst the thousands of submissions in the public interest has been compromised or its author disclosed. Watch the video and learn how to safely whistleblow your information for the greater good.
Information Release, Centre For Investigative Journalism
Related Links:
* WikiLeaks Changes Course Of Afghan War - Multiple Atrocities Exposed
Afghan War Diary, WikiLeaks
* Why The World Needs Free Speech WikiLeaks
Chris Anderson, TED / Julian Assange, WikiLeaks
* Collateral Murder
US military video depicting the indiscriminate slaying of over a dozen people in the Iraqi suburb of New Baghdad -- including two Reuters news staff
WikiLeaks
2. Ana Cantu - Human Guinea Pig In A Drug Trial For $4,800
A testimonial in The American Statesman, by Ana Cantu, who was one of the healthy volunteers --"a human guinea pig" as she describes herself-- in a month long study that tested the effects of Norvir, an HIV drug made by Abbott Laboratories, when coupled with the antidepressant Wellbutrin, made by GlaxoSmithKline. Her first-hand experience provides insight about the immense "pressure for positive results in clinical trials," the level of discomfort a human subject is expected to endure from the adverse effects of the tested drug (or combination of drugs), and the dilemma for drug manufacturers whose drug causes adverse effects so severe, the test subjects in pre-marketing trials drop out in droves. The FDA accepts study results--even if only 7 of 20 subjects complete the study. Companies are loathe to scrap a negative study: they hold on to the last 7 subjects despite severe adverse effects. The "volunteers" suffer for the pay ment which they would forfeit if they quit. "The study started out with 20 subjects...For about a week there were 14 subjects. Then they started dropping...Now, we're down to 7."
Vera Hassner Sharav, AHRP
READ THE NEWS ON ONE CLICK
http://www.theoneclickgroup.co.uk
Posts
